Assessment of additive/nonadditive effects in structure-activity relationships: Implications for iterative drug design

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7552-7562

  Patel, Yogendra ^a,c   Gillet, Valerie J ^a   Howe, Trevor ^b   Pastor, Joaquin ^b,d   Oyarzabal, Julen ^b,d   Willett, Peter ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Johnson and Johnson Pharmaceutical R and D ^*  (Spain)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL METABOLISM; COMBINATORIAL LIBRARY; DRUG DESIGN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57349117629     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801070q     Document Type: Article

References (49)

1. Wess, G. How to escape the bottleneck of medicinal chemistry. Drug Discovery Today 2002, 7, 533-535.
2. Dill, K. A. Additivity principles in biochemistry. J. Biol. Chem. 1997, 272, 701-704.
3. Szwajkajzer, D.; Carey, J. Molecular and biological constraints on ligand-binding affinity and specificity. Biopolymers 1997, 44, 181-198.
4. Jencks, W. P. On the Attribution and Additivity of Binding Energies. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 4046-4050.
5. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
6. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274, 1531-1534.
7. Hajduk, P. J.; Gomtsyan, A.; Didomenico, S.; Cowart, M.; Bayburt, E. K.; Solomon, L.; Severin, J.; Smith, R.; Walter, K.; Holzman, T. F.; Stewart, A.; McGaraughty, S.; Jarvis, M. F.; Kowaluk, E. A.; Fesik, S. W. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 2000, 43, 4781-4786.
8. Szczepankiewicz, B. G.; Liu, G.; Hajduk, P. J.; Abad-Zapatero, C.; Pei, Z. H.; Xin, Z. L.; Lubben, T. H.; Trevillyan, J. M.; Stashko, M. A.; Ballaron, S. J.; Liang, H.; Huang, F.; Hutchins, C. W.; Fesik, S. W.; Jirousek, M. R. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 2003, 125, 4087-4096.
9. Erlanson, D. A.; Wells, J. A.; Braisted, A. C. Tethering: Fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 2004, 33, 199-223.
10. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. A. Site-directed ligand discovery. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9367-9372.
11. Braisted, A. C.; Oslob, J. D.; Delano, W. L.; Hyde, J.; McDowell, R. S.; Waal, N.; Yu, C.; Arkin, M. R.; Raimundo, B. C. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 2003, 125, 3714-3715.
12. Maly, D. J.; Choong, I. C.; Ellman, J. A. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2419-2424.
13. Hindi, S.; Deng, H. T.; James, L.; Kawamura, A. Selective photolabeling of Lck kinase in complex proteome. Bioorg. Med. Chem. Lett. 2006, 16, 5625-5628.
14. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48, 403-413.
15. Stout, T. J.; Sage, C. R.; Stroud, R. M. The additivity of substrate fragments in enzyme-ligand binding. Struct. Folding Des. 1998, 6, 839-848.
16. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem. 2007, 50, 2293-2296.
17. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 2006, 2, 720-723.
18. Hajduk, P. J. Puzzling through fragment-based drug design. Nat. Chem. Biol. 2006, 2, 658-659.
19. Free, S. M.; Wilson, J. W. Mathematical Contribution to Structure-Activity Studies. J. Med. Chem. 1964, 7, 395-399.
20. Green, N. M. Avidin. Adv. Protein Chem. 1975, 29, 85-133.
21. Congreve, M. S.; Davis, D. J.; Devine, L.; Granata, C.; O'Reilly, M.; Wyatt, P. G.; Jhoti, H. Detection of ligands from a dynamic combinatorial library by X-ray crystallography. Angew. Chem., Int. Ed. 2003, 42, 4479-4482.
22. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera, G. M.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997, 119, 5818-5827.
23. Miller, B. G.; Wolfenden, R. Catalytic proficiency: The unusual case of OMP decarboxylase. Annu. Rev. Biochem. 2002, 71, 847-885.
24. Ewing, T. J. A.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411-428.
25. Momany, F. A.; Rone, R. Validation of the General-Purpose Quanta(R)3.2/Charmm(R) Force-Field. J. Comput. Chem. 1992, 13, 888-900.
26. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
27. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
28. Bohm, H. J. Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput.-Aided Mol. Des. 1998, 12, 309-323.
29. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
30. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions 0.1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
31. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
32. Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006, 49, 5912-5931.
33. Fujita, T.; Ban, T. Studies on Structure-Activity Relationship 0.3. Structure-Activity Study of Phenethylamines as Substrates of Biosynthetic Enzymes of Sympathetic Transmitters. J. Med. Chem. 1971, 14, 148-152.
34. Paliakov, E.; Henary, M.; Say, M.; Patterson, S. E.; Parker, A.; Manzel, L.; MacFarlane, D. E.; Bojarski, A. J.; Strekowski, L. Fujita-Ban QSAR analysis and CoMFA study of quinoline antagonists of immunostimulatory CpG-oligodeoxynucleotides. Bioorg. Med. Chem. 2007, 15, 324-332.
35. Vasanthanathan, P.; Lakshmi, M.; Rao, A. R. QSAR study on pyridinone derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitor: a mixed approach. Med. Chem. 2007, 3, 227-232.
36. Pissurlenkar, R. R. S.; Malde, A. K.; Khedkar, S. A.; Coutinho, E. C. Encoding type and position in peptide QSAR: Application to peptides binding to class 1 MHC molecule HLA-A*0201. QSAR Comb. Sci. 2007, 26, 189-203.
37. Globisch, C.; Pajeva, I. K.; Wiese, M. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg. Med. Chem. 2006, 14, 1588-1598.
38. Lee, S. G.; Chmielewski, J. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors. Chem. Biol. 2006, 13, 421-426.
39. Schaper, K. J. Free-Wilson-type analysis of non-additive substituent effects on THPB dopamine receptor affinity using artificial neural networks. Quant. Struct.-Act. Relat. 1999, 18, 354-360.
40. Sehon, C.; McClure, K.; Hack, M.; Morton, M.; Gomez, L.; Li, L. N.; Barrett, T. D.; Shankley, N.; Breitenbucher, J. G. Pyrazole CCK1 receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity. Bioorg. Med. Chem. Lett. 2006, 16, 77-80.
41. Ge, N. X.; Cho, S. J.; Hermsmeier, M.; Poss, M.; Shen, C. F. Testing non-additivity of biological activity in a combinatorial library. Comb. Chem. High Throughput Screening 2002, 5, 147-154.
42. Pipeline Pilot; Scitegic, 9665 Chesapeake Drive, Suite 401, San Diego, CA 92123-1365. Available from SciTegic Inc. at http://www.scitegic.com.
43. Bosmans, J. P. R. M. A.; Love, C. J.; Van Lommen, G. R. E. Preparation of 2,4-diaminopyrimidines as dopamine D4 antagonists. Patent WO9743279 A1, 1997.
44. Andres-Gil, J. I.; Alcazar-Vaca, M. J.; Linares de la Morena, M. L.; Martinez Gonzalez, S.; Oyarzabal Santamarina, J.; Pastor-Fernandez, J.; Vega Ramiro, J. A.; Drinkenburg, W. H. I. M. Preparation of substituted pyrazinone derivatives as α2c-adrenoreceptor antagonists. Patent WO07071639 A1, 2007.
45. Brotherton-Pleiss, C. E.; Dillon, M. P.; Gleason, S. K.; Jen Lin, C. J.; Schoenfeld, R. C.; Villa, M.; Zhai, Y. Preparation of heterocyclic inhibitors of P2 x 3 useful for treating pain, genito-urinary, gastrointestinal, and respiratory disorders. Patent US 2007037974 A1, 2007.
46. Steckler, T. H. W.; Janssens, F. E.; Leenaerts, J. E.; Fernandez-Gadea, F. J.; Gomez-Sanchez, A.; Meert, T. F. Preparation of 4-phenyl-4-(imidazol-2-yl) piperidine derivatives as selective non-peptide §-opioid agonists for treatment of depression and anxiety, Patent WO04089372 A1, 2004.
47. Freyne, E. J. E.; Love, C. J.; Cooymans, L. P.; Vandermaesen, N.; Buijnsters, P. J. J. A.; Willems, M.; Embrechts, W. C. J. Preparation of triazolopyrimidines as glycogen synthase kinase 3 inhibitors. Patent WO05012304 A2, 2005.
48. Holland, J. H. Adaptation in Natural and Artificial Systems; The University of Michigan Press: Ann Arbor, MI, 1975.
49. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graphics Modell. 2002, 20, 269-276.